- Metastatic SCLC
- Metastatic or Unresectable,
Recurrent HNSCC - Relapsed or Refractory
Classical Hodgkin Lymphoma
- Refractory or Relapsed PMBCL
- Advanced Urothelial Carcinoma
- High-Risk Non-muscle Invasive
Bladder Cancer
The following codes may be relevant when billing for KEYTRUDA and its administration. This information is current as of November 2020. The information provided here is compiled from sources believed to be accurate, but Merck makes no representation that it is accurate. Information about HCPCS codes is based on guidance issued by the CMS applicable to Medicare Part B and may not apply to other public or private payers. Consult the relevant manual and/or other guidelines for a description of each code to determine the appropriateness of its use and for information on additional codes. Diagnosis codes should be selected only by a health care professional. This information is subject to change. Merck cautions that payer-coding requirements vary and can frequently change, so it is important to regularly check with each payer or, where applicable, the Medicare Administrative Contractor as to payer-specific requirements.
You are solely responsible for determining the appropriate codes and for any action you take in billing. The information provided here is not intended to be definitive or exhaustive, and is not intended to replace the guidance of a qualified professional advisor. Diagnosis codes should be selected only by a health care professional. Merck and its agents make no warranties or guarantees, expressed or implied, concerning the accuracy or appropriateness of this information for your particular use given the frequent changes in public and private payer billing. The use of this information does not guarantee payment or that any payment received will cover your costs.
The NDC is typically required when submitting a claim with a miscellaneous HCPCS code. Please consult with the payer to understand specific billing requirements.
PRODUCT | |
KEYTRUDA® (pembrolizumab) injection 100 mg | |
PACKAGE | NDC |
Carton containing one 100 mg/4 mL (25 mg/mL), single-dose vial | 0006-3026-02 |
Carton containing two 100 mg/4 mL (25 mg/mL), single-dose vials | 0006-3026-04 |
Please note: The NDCs above are the billable NDCs that appear on the cartons. The NDC on the vial should not be used for billing purposes.
Below is a list of possible codes that could be relevant for KEYTRUDA and its administration. Please consult with the applicable payer to understand the payer’s specific billing requirements.